163 related articles for article (PubMed ID: 29408852)
1. High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy.
Qin YZ; Zhao T; Zhu HH; Wang J; Jia JS; Lai YY; Zhao XS; Shi HX; Liu YR; Jiang H; Huang XJ; Jiang Q
Med Sci Monit; 2018 Feb; 24():758-767. PubMed ID: 29408852
[TBL] [Abstract][Full Text] [Related]
2. Optimal time-points for detecting expression levels of BAALC, EVI1, and WT1 genes in patients with acute myeloid leukemia: a meta-analysis.
Yuen KY; Lin XY; Zhou YZ; Luo H; Liu Y; Xu LH
Hematology; 2021 Dec; 26(1):995-1006. PubMed ID: 34871539
[TBL] [Abstract][Full Text] [Related]
3. High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk.
Xu N; Chen WM; Li LD; Long LY; Wang X; Jiang Q; Jiang H; Huang XJ; Qin YZ
Clin Exp Med; 2023 Oct; 23(6):2629-2638. PubMed ID: 36637581
[TBL] [Abstract][Full Text] [Related]
4. High
Dao FT; Chen WM; Long LY; Li LD; Yang L; Wang J; Liu YR; Jiang H; Zhang XH; Jiang Q; Qin YZ
Leuk Lymphoma; 2021 Jan; 62(1):185-193. PubMed ID: 32902355
[TBL] [Abstract][Full Text] [Related]
5. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
6. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
7. [EVI1 expression, clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia].
He XF; Wang QR; Cen JN; Qiu HY; Sun AN; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):936-941. PubMed ID: 27995876
[TBL] [Abstract][Full Text] [Related]
8. The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
Liu XX; Pan XA; Gao MG; Kong J; Jiang H; Chang YJ; Zhang XH; Wang Y; Liu KY; Chen Z; Zhao XS; Huang XJ
Int J Lab Hematol; 2023 Apr; 45(2):195-203. PubMed ID: 36358022
[TBL] [Abstract][Full Text] [Related]
9. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
10. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
Ho PA; Alonzo TA; Gerbing RB; Pollard JA; Hirsch B; Raimondi SC; Cooper T; Gamis AS; Meshinchi S
Br J Haematol; 2013 Sep; 162(5):670-7. PubMed ID: 23826732
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
Wu X; Wang H; Deng J; Zheng X; Ling Y; Gong Y
Ann Hematol; 2019 Nov; 98(11):2485-2496. PubMed ID: 31482295
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
[TBL] [Abstract][Full Text] [Related]
14. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
15. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
17. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
[TBL] [Abstract][Full Text] [Related]
18. Low EVI1 expression at diagnosis predicted poor outcomes in pediatric Ph-negative B cell precursor acute lymphoblastic leukemia patients.
Yang L; Dao FT; Lu AD; Chen WM; Li LD; Long LY; Liu YR; Liu KY; Zhang LP; Qin YZ
Pediatr Hematol Oncol; 2022 Mar; 39(2):97-107. PubMed ID: 34156313
[TBL] [Abstract][Full Text] [Related]
19. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.
Santamaría CM; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodriguez JN; Fernández-Abellán P; Bárez A; Peñarrubia MJ; Balanzategui A; Vidriales MB; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel JF; Gonzalez M
Blood; 2009 Jul; 114(1):148-52. PubMed ID: 19398719
[TBL] [Abstract][Full Text] [Related]
20. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
